Dynamic Advisor Solutions LLC Acquires 12,116 Shares of Pfizer Inc. (NYSE:PFE)

Dynamic Advisor Solutions LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 12.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 112,926 shares of the biopharmaceutical company’s stock after acquiring an additional 12,116 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Pfizer were worth $4,422,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Usca Ria LLC raised its position in shares of Pfizer by 11.6% during the 2nd quarter. Usca Ria LLC now owns 504,526 shares of the biopharmaceutical company’s stock valued at $19,757,000 after acquiring an additional 52,362 shares during the last quarter. Cito Capital Group LLC increased its position in shares of Pfizer by 59.6% in the 1st quarter. Cito Capital Group LLC now owns 38,831 shares of the biopharmaceutical company’s stock valued at $1,407,000 after buying an additional 14,500 shares in the last quarter. Advisor Group Holdings Inc. increased its position in shares of Pfizer by 4.4% in the 2nd quarter. Advisor Group Holdings Inc. now owns 2,090,666 shares of the biopharmaceutical company’s stock valued at $81,925,000 after buying an additional 88,276 shares in the last quarter. Guggenheim Capital LLC increased its position in shares of Pfizer by 2.8% in the 1st quarter. Guggenheim Capital LLC now owns 1,461,508 shares of the biopharmaceutical company’s stock valued at $52,950,000 after buying an additional 40,497 shares in the last quarter. Finally, Carolina Wealth Advisors LLC increased its position in shares of Pfizer by 7.1% in the 2nd quarter. Carolina Wealth Advisors LLC now owns 112,745 shares of the biopharmaceutical company’s stock valued at $4,415,000 after buying an additional 7,456 shares in the last quarter. Institutional investors own 64.93% of the company’s stock.

PFE has been the subject of a number of recent analyst reports. Morgan Stanley upped their price objective on shares of Pfizer from $42.00 to $45.00 and gave the company an “equal weight” rating in a research report on Thursday, July 29th. Truist initiated coverage on shares of Pfizer in a research report on Tuesday, July 27th. They issued a “buy” rating and a $43.00 price objective for the company. Royal Bank of Canada set a $44.00 price objective on shares of Pfizer in a research report on Thursday, July 29th. JPMorgan Chase & Co. upped their target price on shares of Pfizer from $40.00 to $42.00 and gave the stock a “neutral” rating in a research note on Monday. Finally, Mizuho upped their target price on shares of Pfizer from $42.00 to $43.00 and gave the stock a “neutral” rating in a research note on Friday, July 30th. Eleven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $42.77.

Shares of Pfizer stock traded up $0.21 during trading hours on Wednesday, reaching $44.92. 558,481 shares of the company’s stock were exchanged, compared to its average volume of 30,836,189. The company has a 50 day moving average of $44.74 and a two-hundred day moving average of $40.35. Pfizer Inc. has a fifty-two week low of $33.36 and a fifty-two week high of $51.86. The company has a current ratio of 1.37, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50. The stock has a market cap of $251.85 billion, a P/E ratio of 19.36, a P/E/G ratio of 1.58 and a beta of 0.74.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, July 28th. The biopharmaceutical company reported $1.07 EPS for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.10. Pfizer had a net margin of 23.06% and a return on equity of 26.49%. The company had revenue of $18.98 billion during the quarter, compared to the consensus estimate of $17.54 billion. During the same period in the prior year, the business posted $0.78 EPS. As a group, analysts expect that Pfizer Inc. will post 4.12 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 7th. Stockholders of record on Friday, July 30th were paid a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, July 29th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.47%. Pfizer’s dividend payout ratio is 70.27%.

In other news, SVP Jennifer B. Damico sold 2,500 shares of the company’s stock in a transaction dated Friday, July 30th. The shares were sold at an average price of $42.86, for a total value of $107,150.00. Following the sale, the senior vice president now directly owns 11,430 shares of the company’s stock, valued at approximately $489,889.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Jennifer B. Damico sold 1,661 shares of the stock in a transaction dated Friday, August 13th. The shares were sold at an average price of $48.30, for a total transaction of $80,226.30. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.

About Pfizer

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Recommended Story: How to Use the MarketBeat Retirement Calculator

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.